Original Source
New Pancreatic Cancer Drug 'Daraxonrasib' Offers Hope for Extended Survival
A New Horizon in Pancreatic Cancer Treatment
According to France 24, a new experimental drug named Daraxonrasib, announced in Europe, is offering hope to patients suffering from pancreatic cancer. Dr. Thomas Pudlarz, a medical oncologist, explained that pancreatic cancer is one of the most lethal cancers, with little progress in treatment over decades. This new drug blocks a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases, a target that had eluded treatment for decades. While it may not cure the cancer, it offers the potential for extended survival, a significant breakthrough eagerly anticipated by the medical community.
Distinguishing Features and Expected Benefits of Daraxonrasib
Dr. Pudlarz highlighted that while existing pancreatic cancer treatments largely rely on cytotoxic chemotherapy, Daraxonrasib is a targeted therapy that specifically inhibits a mutated gene. Furthermore, this treatment is administered as an oral pill, improving patient convenience compared to intravenous treatments. Currently in phase 3 clinical trials, the drug is awaiting approval from French authorities, suggesting that patients could soon gain access to this promising therapy.
Such targeted therapies have been effective in other cancer types like breast and colorectal cancer but had previously failed in pancreatic cancer. Therefore, the advent of Daraxonrasib is considered a crucial advancement in pancreatic cancer treatment, expected to improve overall survival and quality of life for patients with advanced disease. However, Dr. Pudlarz underscored that it is not a cure and should be administered alongside palliative and supportive care, including nutrition management and pain relief.
*Source: France24, YouTube: France 24 English (2026-06-02)*
Related Articles
📧 Daily Newsletter
Get the daily global news briefing in your inbox every morning.
It's still free.